FDA Approves Zenocutuzumab for NRG1 Fusion-Positive Cholangiocarcinoma
The FDA has approved Partner Therapeutics‘ BIZENGRI® (zenocutuzumab) for the treatment of NRG1 fusion-positive cholangiocarcinoma. Alongside the approval, the company secured a National Priority Voucher (NPV), providing a strategic pathway ... Read More